射频消融联合索拉非尼对兔VX2肝癌模型残留病灶及机体免疫系统的影响

Radiofrequency ablation (RFA) and multikinase inhibitor sorafenib are widely used therapy for advanced hepatocellular carcinoma (HCC). This study discusses the influence of radiofrequency ablation in combination with sorafenib therapy on residual lesion and immune system in rabbit VX2 liver cancer model. The experimental rabbits were implanted with two VX2 tumours in left and right lobes of liver, and then RFA therapy was performed for left lobe lesions and combined with oral sorafenib. By comparing the relationship between the right lobe lesions reduction degree and vascular endothelial growth factor (VEGF) protein expression of tumor tissue and T cell subgroup, inflammatory factor levels with the control groups,we are hopeful to know if combined treatment is more effective to reduce the residual tumor lesions, and to discuss if this combined treatment affect the residual tumor by regulating immune system in addition to inhibit VEGF protein expression. This result will lead to further joint radiofrequency ablation, sorafenib and immune therapy and provide the theory basis for the comprehensive treatment of liver cancer.

射频消融（RFA）技术和多激酶抑制剂索拉非尼目前广泛应用于进展期肝细胞肝癌（HCC）的治疗中，同时两种治疗均可对患者机体免疫系统产生影响。本项研究探讨RFA联合索拉非尼对兔VX2多发肝癌模型残留病灶及对机体免疫系统的影响。在实验兔左右叶分别种植VX2肿瘤建立兔肝癌双瘤模型，RFA治疗其左叶病灶并联合口服索拉非尼。通过与对照组比较治疗后右叶病灶的缩小程度及其与肿瘤组织血管内皮生长因子（VEGF）的蛋白表达、机体T细胞亚群、各种炎症因子水平的关系，了解联合治疗后是否更有利于残留肿瘤病灶的减小，并探讨联合治疗除了通过抑制VEGF蛋白表达外，是否也通过对机体免疫系统的作用而影响到残留肿瘤的消涨，为今后进一步联合射频消融、索拉非尼与免疫治疗等手段，综合治疗肝癌提供理论依据。

射频消融（RFA）技术和多激酶抑制剂索拉非尼目前广泛应用于进展期肝细胞肝癌（HCC）的治疗中，同时两种治疗均可对患者机体免疫系统产生影响。本项研究探讨RFA联合索拉非尼对兔VX2多发肝癌模型残留病灶及对机体免疫系统的影响。在实验兔左右叶分别种植VX2肿瘤建立兔肝癌双瘤模型，RFA治疗其中一病灶并联合口服索拉非尼。通过与对照组比较治疗后另一病灶的缩小程度及其与肿瘤组织血管内皮生长因子（VEGF）的蛋白表达、机体T细胞亚群、各种炎症因子水平的关系，联合治疗后更有利于残留肿瘤病灶的减小，并探讨联合治疗对VEGF蛋白的抑制作用，以及对机体免疫系统的复杂作用，为今后进一步联合射频消融、索拉非尼与免疫治疗等手段，综合治疗肝癌提供理论依据。